BCRX
BioCryst Pharmaceuticals, Inc.$9.86+0.70 (+7.64%)Prev Close$9.16·MCap$1.80B·P/E6.79·Vol6.84M·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
11
$4.59M
◆
Net Activity
Net Seller
$4.59M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at BioCryst Pharmaceuticals, Inc. (BCRX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 11 insider sales totaling $4.59M. The most recent insider transaction was by Barnes Alane P (officer: Chief Legal Officer), who sold $1.37M worth of shares on Mar 18, 2026. BioCryst Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.80B.
BCRX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | Barnes Alane P | officer: Chief Legal Officer | Sell | 150,000 | $9.15 | $1.37M | 400,703 |
| Dec 19, 2025 | Barnes Alane P | Chief Legal Officer | Sell | 38,675 | $7.55 | $291.8K | 0 |
| Dec 19, 2025 | Gayer Charles K | President and CCO | Sell | 11,477 | $7.41 | $85.0K | 0 |
| Dec 19, 2025 | Stonehouse Jon P | Chief Executive Officer | Sell | 61,793 | $7.41 | $457.9K | 0 |
| Dec 12, 2025 | Barnes Alane P | Chief Legal Officer | Sell | 29,750 | $7.63 | $226.9K | 0 |
| Dec 12, 2025 | Gayer Charles K | President and CCO | Sell | 8,181 | $7.57 | $61.9K | 0 |
| Dec 12, 2025 | Stonehouse Jon P | Chief Executive Officer | Sell | 27,368 | $7.57 | $207.2K | 0 |
| Dec 1, 2025 | Barnes Alane P | Chief Legal Officer | Sell | 161,680 | $7.21 | $1.16M | 0 |
| Nov 13, 2025 | SANDERS MACHELLE | Director | Sell | 9,600 | $7.14 | $68.5K | 0 |
| Aug 13, 2025 | HEGGIE THERESA | Director | Sell | 70,000 | $8.51 | $595.9K | 0 |
| Mar 31, 2025 | Thackray Helen M. | Chief R&D Officer | Sell | 7,525 | $7.50 | $56.4K | 0 |
| Dec 19, 2024 | Gayer Charles K | Chief Commercial Officer | Sell | 2,461 | $7.39 | $18.2K | 0 |
| Dec 19, 2024 | Stonehouse Jon P | President & CEO | Sell | 14,010 | $7.39 | $103.5K | 0 |
| Dec 19, 2024 | Thackray Helen M. | Chief R&D Officer | Sell | 6,096 | $7.39 | $45.0K | 0 |
| Dec 14, 2024 | Barnes Alane P | Chief Legal Officer | Sell | 8,613 | $7.53 | $64.9K | 0 |
| Dec 14, 2024 | Doyle Anthony | Chief Financial Officer | Sell | 7,890 | $7.53 | $59.4K | 0 |
| Dec 14, 2024 | Gayer Charles K | Chief Commercial Officer | Sell | 8,251 | $7.53 | $62.1K | 0 |
| Dec 14, 2024 | Stonehouse Jon P | President & CEO | Sell | 27,525 | $7.53 | $207.3K | 0 |
| Dec 14, 2024 | Thackray Helen M. | Chief R&D Officer | Sell | 7,150 | $7.53 | $53.8K | 0 |
| Dec 13, 2024 | Hutson Nancy J | Director | Sell | 7,000 | $7.54 | $52.8K | 0 |
| Jun 24, 2024 | McKee Amy E | Director | Sell | 8,600 | $6.32 | $54.4K | 0 |
| Jun 17, 2024 | SANDERS MACHELLE | Director | Sell | 4,689 | $6.00 | $28.1K | 0 |
| Jun 12, 2024 | HEGGIE THERESA | Director | Sell | 6,698 | $6.11 | $40.9K | 0 |
| May 30, 2024 | LEVIN ALAN G | Director | Buy | 7,861 | $6.36 | $50.0K | 0 |
| May 24, 2024 | ASELAGE STEVE | Director | Buy | 2,500 | $6.40 | $16.0K | 0 |
| May 20, 2024 | Hutson Nancy J | Director | Buy | 5,000 | $6.38 | $31.9K | 0 |
| May 20, 2024 | MILANO VINCENT | Director | Buy | 15,000 | $6.25 | $93.8K | 0 |
| May 14, 2024 | Doyle Anthony | Chief Financial Officer | Buy | 36,300 | $5.57 | $202.2K | 0 |
| May 14, 2024 | Thackray Helen M. | Chief R&D Officer | Buy | 30,000 | $5.86 | $175.8K | 0 |
| May 13, 2024 | Barnes Alane P | Chief Legal Officer | Buy | 5,000 | $5.53 | $27.6K | 0 |
| May 13, 2024 | Galson Steven K | Director | Buy | 21,940 | $5.49 | $120.5K | 0 |
| May 13, 2024 | Gayer Charles K | Chief Commercial Officer | Buy | 30,000 | $5.47 | $164.1K | 0 |
| May 13, 2024 | Stonehouse Jon P | President & CEO | Buy | 30,000 | $5.55 | $166.5K | 0 |
| Mar 31, 2024 | Thackray Helen M. | Chief R&D Officer | Sell | 7,525 | $5.08 | $38.2K | 0 |
| Dec 19, 2023 | Gayer Charles K | Chief Commercial Officer | Sell | 2,482 | $6.05 | $15.0K | 0 |
| Dec 19, 2023 | Stonehouse Jon P | President & CEO | Sell | 14,089 | $6.05 | $85.2K | 0 |
| Dec 19, 2023 | Thackray Helen M. | Chief R&D Officer | Sell | 5,580 | $6.05 | $33.8K | 0 |
| Dec 14, 2023 | Barnes Alane P | Chief Legal Officer | Sell | 4,015 | $6.43 | $25.8K | 0 |
| Dec 14, 2023 | Doyle Anthony | Chief Financial Officer | Sell | 5,475 | $6.43 | $35.2K | 0 |
| Dec 14, 2023 | Gayer Charles K | Chief Commercial Officer | Sell | 5,840 | $6.43 | $37.6K | 0 |
| Dec 14, 2023 | Stonehouse Jon P | President & CEO | Sell | 13,592 | $6.43 | $87.4K | 0 |
| Dec 14, 2023 | Thackray Helen M. | Chief R&D Officer | Sell | 3,031 | $6.43 | $19.5K | 0 |
| Jun 13, 2023 | Hutson Nancy J | Director | Sell | 12,866 | $8.04 | $103.4K | 0 |
| Jun 13, 2023 | SANDERS MACHELLE | Director | Sell | 4,000 | $7.98 | $31.9K | 0 |
| Apr 3, 2023 | Thackray Helen M. | Chief R&D Officer | Sell | 7,000 | $8.29 | $58.0K | 0 |
| Feb 1, 2023 | Stonehouse Jon P | President & CEO | Sell | 100,000 | $10.38 | $1.04M | 0 |
| Dec 15, 2022 | Barnes Alane P | Chief Legal Officer | Sell | 4,175 | $10.88 | $45.4K | 0 |
| Dec 15, 2022 | Doyle Anthony | Chief Financial Officer | Sell | 5,700 | $10.90 | $62.1K | 0 |
| Dec 15, 2022 | Gayer Charles K | Chief Commercial Officer | Sell | 6,100 | $10.90 | $66.5K | 0 |
| Dec 15, 2022 | Jones Michael L | Exec. Director, Finance - PAO | Sell | 445 | $10.90 | $4.9K | 0 |
Showing 1–50 of 78
1 / 2
BCRX Insider Buying Activity
The following table shows recent insider purchases of BioCryst Pharmaceuticals, Inc. (BCRX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 30, 2024 | LEVIN ALAN G | Director | Buy | 7,861 | $6.36 | $50.0K | 0 |
| May 24, 2024 | ASELAGE STEVE | Director | Buy | 2,500 | $6.40 | $16.0K | 0 |
| May 20, 2024 | Hutson Nancy J | Director | Buy | 5,000 | $6.38 | $31.9K | 0 |
| May 20, 2024 | MILANO VINCENT | Director | Buy | 15,000 | $6.25 | $93.8K | 0 |
| May 14, 2024 | Doyle Anthony | Chief Financial Officer | Buy | 36,300 | $5.57 | $202.2K | 0 |
| May 14, 2024 | Thackray Helen M. | Chief R&D Officer | Buy | 30,000 | $5.86 | $175.8K | 0 |
| May 13, 2024 | Barnes Alane P | Chief Legal Officer | Buy | 5,000 | $5.53 | $27.6K | 0 |
| May 13, 2024 | Galson Steven K | Director | Buy | 21,940 | $5.49 | $120.5K | 0 |
| May 13, 2024 | Gayer Charles K | Chief Commercial Officer | Buy | 30,000 | $5.47 | $164.1K | 0 |
| May 13, 2024 | Stonehouse Jon P | President & CEO | Buy | 30,000 | $5.55 | $166.5K | 0 |
BCRX Insider Selling Activity
The following table shows recent insider sales of BioCryst Pharmaceuticals, Inc. (BCRX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 18, 2026 | Barnes Alane P | officer: Chief Legal Officer | Sell | 150,000 | $9.15 | $1.37M | 400,703 |
| Dec 19, 2025 | Barnes Alane P | Chief Legal Officer | Sell | 38,675 | $7.55 | $291.8K | 0 |
| Dec 19, 2025 | Gayer Charles K | President and CCO | Sell | 11,477 | $7.41 | $85.0K | 0 |
| Dec 19, 2025 | Stonehouse Jon P | Chief Executive Officer | Sell | 61,793 | $7.41 | $457.9K | 0 |
| Dec 12, 2025 | Barnes Alane P | Chief Legal Officer | Sell | 29,750 | $7.63 | $226.9K | 0 |
| Dec 12, 2025 | Gayer Charles K | President and CCO | Sell | 8,181 | $7.57 | $61.9K | 0 |
| Dec 12, 2025 | Stonehouse Jon P | Chief Executive Officer | Sell | 27,368 | $7.57 | $207.2K | 0 |
| Dec 1, 2025 | Barnes Alane P | Chief Legal Officer | Sell | 161,680 | $7.21 | $1.16M | 0 |
| Nov 13, 2025 | SANDERS MACHELLE | Director | Sell | 9,600 | $7.14 | $68.5K | 0 |
| Aug 13, 2025 | HEGGIE THERESA | Director | Sell | 70,000 | $8.51 | $595.9K | 0 |
| Mar 31, 2025 | Thackray Helen M. | Chief R&D Officer | Sell | 7,525 | $7.50 | $56.4K | 0 |
| Dec 19, 2024 | Gayer Charles K | Chief Commercial Officer | Sell | 2,461 | $7.39 | $18.2K | 0 |
| Dec 19, 2024 | Stonehouse Jon P | President & CEO | Sell | 14,010 | $7.39 | $103.5K | 0 |
| Dec 19, 2024 | Thackray Helen M. | Chief R&D Officer | Sell | 6,096 | $7.39 | $45.0K | 0 |
| Dec 14, 2024 | Barnes Alane P | Chief Legal Officer | Sell | 8,613 | $7.53 | $64.9K | 0 |
| Dec 14, 2024 | Doyle Anthony | Chief Financial Officer | Sell | 7,890 | $7.53 | $59.4K | 0 |
| Dec 14, 2024 | Gayer Charles K | Chief Commercial Officer | Sell | 8,251 | $7.53 | $62.1K | 0 |
| Dec 14, 2024 | Stonehouse Jon P | President & CEO | Sell | 27,525 | $7.53 | $207.3K | 0 |
| Dec 14, 2024 | Thackray Helen M. | Chief R&D Officer | Sell | 7,150 | $7.53 | $53.8K | 0 |
| Dec 13, 2024 | Hutson Nancy J | Director | Sell | 7,000 | $7.54 | $52.8K | 0 |
| Jun 24, 2024 | McKee Amy E | Director | Sell | 8,600 | $6.32 | $54.4K | 0 |
| Jun 17, 2024 | SANDERS MACHELLE | Director | Sell | 4,689 | $6.00 | $28.1K | 0 |
| Jun 12, 2024 | HEGGIE THERESA | Director | Sell | 6,698 | $6.11 | $40.9K | 0 |
| Mar 31, 2024 | Thackray Helen M. | Chief R&D Officer | Sell | 7,525 | $5.08 | $38.2K | 0 |
| Dec 19, 2023 | Gayer Charles K | Chief Commercial Officer | Sell | 2,482 | $6.05 | $15.0K | 0 |
| Dec 19, 2023 | Stonehouse Jon P | President & CEO | Sell | 14,089 | $6.05 | $85.2K | 0 |
| Dec 19, 2023 | Thackray Helen M. | Chief R&D Officer | Sell | 5,580 | $6.05 | $33.8K | 0 |
| Dec 14, 2023 | Barnes Alane P | Chief Legal Officer | Sell | 4,015 | $6.43 | $25.8K | 0 |
| Dec 14, 2023 | Doyle Anthony | Chief Financial Officer | Sell | 5,475 | $6.43 | $35.2K | 0 |
| Dec 14, 2023 | Gayer Charles K | Chief Commercial Officer | Sell | 5,840 | $6.43 | $37.6K | 0 |
| Dec 14, 2023 | Stonehouse Jon P | President & CEO | Sell | 13,592 | $6.43 | $87.4K | 0 |
| Dec 14, 2023 | Thackray Helen M. | Chief R&D Officer | Sell | 3,031 | $6.43 | $19.5K | 0 |
| Jun 13, 2023 | Hutson Nancy J | Director | Sell | 12,866 | $8.04 | $103.4K | 0 |
| Jun 13, 2023 | SANDERS MACHELLE | Director | Sell | 4,000 | $7.98 | $31.9K | 0 |
| Apr 3, 2023 | Thackray Helen M. | Chief R&D Officer | Sell | 7,000 | $8.29 | $58.0K | 0 |
| Feb 1, 2023 | Stonehouse Jon P | President & CEO | Sell | 100,000 | $10.38 | $1.04M | 0 |
| Dec 15, 2022 | Barnes Alane P | Chief Legal Officer | Sell | 4,175 | $10.88 | $45.4K | 0 |
| Dec 15, 2022 | Doyle Anthony | Chief Financial Officer | Sell | 5,700 | $10.90 | $62.1K | 0 |
| Dec 15, 2022 | Gayer Charles K | Chief Commercial Officer | Sell | 6,100 | $10.90 | $66.5K | 0 |
| Dec 15, 2022 | Jones Michael L | Exec. Director, Finance - PAO | Sell | 445 | $10.90 | $4.9K | 0 |
BCRX Insiders
Similar Stocks to BCRX
VRTX
Vertex Pharmaceuticals Incorporated
$458.39+1.50%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$739.88-0.56%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$310.89-1.27%
$42.07B
INSM
Insmed Incorporated
$143.59+0.62%
$30.07B
UTHR
United Therapeutics Corporation
$528.14-0.42%
$23.50B
MRNA
Moderna, Inc.
$52.36-0.21%
$20.76B
ROIV
Roivant Sciences Ltd.
$27.73-0.29%
$20.08B
RPRX
Royalty Pharma plc
$45.69-0.24%
$19.56B